Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
PWNHealth will provide physician oversight and genetic counseling for Picture Genetics, a new line of three genetic tests from Fulgent aimed at consumers.
The company published a quality assurance study for the Panorama test last month and is wrapping up the SMART study, which has enrolled 20,000 women.
The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.
Using single-cell sequencing and an in vitro culture system, researchers followed transcriptomic and epigenomic features over time in three main embryonic cell lineages.
Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
The Cyprus-based company has been offering a cell-free DNA-based noninvasive prenatal test for fetal aneuploidies, called Veracity, since 2015.
The partners will request samples from more than 2,500 existing and new participants in the foundation's Preeclampsia Registry for sequencing analysis.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
The company is hoping to add outreach to make sure individuals who want counseling get it, and to better understand the reasons why others might not.
The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.
Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.
The funding will be used to support clinical validation and expand market access for the firm's endometriosis diagnostic test.
A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports.
The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US.
Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring.
In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.